［1］杨文英.中国糖尿病的流行特点及变化趋势［J］.中国科学:生命科学,2018,48(08):812-819.
YANG WY.Prevalence characteristics and change trend of diabetes in China［J］.Chinese Science:Life Science,2018,48(08):812-819.
[2]赵佳,韩雪,谢梦,等.2型糖尿病并发恶性肿瘤患者的流行病学分析［J］.中国慢性病预防与控制,2018,26(07):514-516.
ZHAO J,HAN X,XIE M,et al.Epidemiological analysis of patients with type 2 diabetes mellitus complicated with malignant tumor［J］.Chinese Journal of Chronic Disease Prevention and Control,2018,26(07):514-516.
[3]张瑞.GLP-1受体激动剂、DPP4抑制剂对2型糖尿病患者肿瘤发生与发展的影响［D］.重庆：第三军医大学,2014.
ZHANG R.Effects of GLP-1 receptor agonist and DPP4 inhibitor on tumorigenesis and development of type 2 diabetes mellitus patients［D］.Chongqing:Third Military Medical University,2014.
[4]许芳芳,王楠,李刚强,等.人胰高血糖素样肽-1的研究与应用进展［J］.生物技术通报,2016,32(06):30-37.
XU FF,WANG N,LI GQ,et al.Research and application progress of human glucagon-like peptide-1［J］.Biotechnology Bulletin,2016,32(06):30-37.
[5]洪天配.GLP-1药物抑制胰腺癌进展的作用及其机制:实情或幻境［A］.中华医学会、中华医学会内分泌学分会.中华医学会第十三次全国内分泌学学术会议会议指南［C］.中华医学会、中华医学会内分泌学分会:中华医学会,2014:2.
HONG TP.Effect of GLP-1 drug on pancreatic cancer progress and its mechanism:Reality or illusion ［A］.Chinese Medical Association,Endocrine Credit Association of Chinese Medical Association.Guidelines for the 13th National Endocrine Academic Conference of Chinese Medical Association ［C］.Chinese Medical Association,Endocrine Credit Association of Chinese Medical Association:Chinese Medical Association,2014:2.
[6] CASES AI,OHTSUKA T,KIMURA H,et al.Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer［J］.Oncology Reports,2015,34(4):1717-1725.
[7] NACHNANI JS,BULCHANDANI DG,NOOKALA A,et al.Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas［J］.Diabetologia,2010,53(1):153-159.
[8] GOTFREDSEN CF,MLCK AM,THORUP I,et al.The human GLP-1 analogs liraglutide and semaglutide:Absence of histopathological effects on the pancreas in nonhuman primates［J］.Diabetes,2014,63(7):2486-2497.
[9] DAL MOLIN M,KIM H,BLACKFORD A,et al.Glucagon-like peptide-1 receptor expression in normal and neoplastic human pancreatic tissues［J］.Pancreas,2016,45(4):613-619.
[10]GUO X,YANG Q,DONG J,et al.Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients:A systematic review［J］.Clinical Drug Investigation,2016,36(6):433-441.
[11]MONTVIDA O,GREEN JB,ATHERTON J,et al.Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs,when added to metformin:Real world evidence in people with type 2 diabetes［J］.Diabetic Medicine,2019,36(4):491-498.
[12]ZHAO H,WANG L,WEI R,et al.Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway［J］.Diabetes Obesity & Metabolism,2014,16(9):850-860.
[13]ZHAO H,WEI R,WANG L,et al.Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner［J］.American Journal of Physiology,Endocrinology and Metabolism,2014,306(12):E1431-1441.
[14]LUNATI ME,GRANCINI V,COLOMBO C,et al.Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment［J］.Metabolism:Clinical and Experimental,2016,65(1):1-6.
[15]VAHLE JL,BYRD RA,BLACKBOURNE JL,et al.Effects of dulaglutide on thyroid C cells and serum calcitonin in male monkeys［J］.Endocrinology,2015,156(7):2409-2416.
[16]张一馨,匡洪宇.胰高血糖素样肽-1与癌症相关性的研究进展［J］.癌症进展,2015,13(03):269-271.
ZHANG YX,KUANG HY.Research progress on the correlation between glucagon-like peptide-1 and cancer［J］.Cancer Progress,2015,13(03):269-271.
[17]孙晓宇,张丽梅.MAPK12在甲状腺乳头状癌中的表达及临床意义［J］.临床检验杂志(电子版),2019,8(01):189-190.
SUN XY,ZHANG LM.Expression and clinical significance of MAPK12 in thyroid papillary carcinoma ［J］.Journal of Clinical Examination (electronic edition),2019,8(01):189-190.
[18]曾曦,陈嘉,田奕.GLP-1R和CK17在甲状腺乳头状癌中的表达及临床意义［J］.重庆医学,2017,46(07):919-922.
ZENG X,CHEN J,TIAN Y.Expression and clinical significance of GLP-1R and CK17 in thyroid papillary carcinoma［J］.Chongqing Medical Journal,2017,46(07):919-922.
[19]HE L,ZHANG S,ZHANG X,et al.Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer［J］.OncoTargets and Therapy,2017,10:5621-5631.
[20]王宇,宋淑芳.我国子宫内膜癌流行病学特征及发病高危因素的研究进展［J］.世界最新医学信息文摘,2018,18(16):41-42.
WANG Y,SONG SF.Research progress on epidemiological characteristics and risk factors of endometrial cancer in China［J］.World Latest Medical Information Digest,2008,18(16):41-42.
[21]ZHANG Y,XU F,LIANG H,et al.Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice［J］.Oncology Reports,2016,35(3):1340-1348.
[22]KANDA R,HIRAIKE H,WADA-HIRAIKE O,et al.Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer［J］.BMC Cancer,2018,18(1):657.
[23]MARZIONI M,ALPINI G,SACCOMANNO S,et al.Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis［J］.Gastroenterology,2007,133(1):244-255.
[24]MARZIONI M,ALPINI G,SACCOMANNO S,et al.Exendin-4,a glucagon-like peptide 1 receptor agonist,protects cholangiocytes from apoptosis［J］.Gut,2009,58(7):990.
[25]CHEN BD,ZHAO WC,DONG JD,et al.Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues［J］.Molecular Biology Reports,2014,41(7):4313-4320.
[26]FAILLIE JL,YU OH,YIN H,et al.Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus［J］.JAMA Internal Medicine,2016,176(10):1474-1481.
[27]ABRAHAMI D,DOUROS A,YIN H,et al.Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes:Population based cohort study［J］.BMJ (Clinical Research ed.),2018,363:k4880.
[28]CHEN BD,ZHAO WC,JIA QA,et al.Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model［J］.International Journal of Molecular Sciences,2013,14(12):24293-24304.